<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04586699</url>
  </required_header>
  <id_info>
    <org_study_id>MediTMS</org_study_id>
    <nct_id>NCT04586699</nct_id>
  </id_info>
  <brief_title>Meditation Accelerated Brain Stimulation for Depression</brief_title>
  <acronym>MediTMS</acronym>
  <official_title>Meditation Accelerated Brain Stimulation for Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Repetitive Transcranial magnetic stimulation (rTMS) is an FDA-approved treatment for&#xD;
      depression that involves brief magnetic stimulation pulses on the dorsolateral prefrontal&#xD;
      cortex (DLPFC) brain region. The ultimate goal of this treatment is to increase excitability&#xD;
      and long-term plasticity in DLPFC, a brain region shown to be hypo-active in depression.&#xD;
      Unfortunately, rTMS only has low to moderate efficacy; remission rates for patients range&#xD;
      from ~15-30% in large randomized controlled trials. The focus of this research is to develop&#xD;
      a next-generation rTMS protocol that is guided by the basic principles underlying brain&#xD;
      plasticity, in order to improve the efficacy of rTMS for the treatment of depression.&#xD;
      Specifically, in this study the investigators will test rTMS paired with a&#xD;
      depression-relevant cognitive state of internal attention.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Repetitive Transcranial magnetic stimulation (rTMS) is an FDA-approved treatment for&#xD;
      depression that involves brief magnetic stimulation pulses on the dorsolateral prefrontal&#xD;
      cortex (DLPFC) brain region. The ultimate goal of this treatment is to increase excitability&#xD;
      and long-term plasticity in DLPFC, a brain region shown to be hypo-active in depression.&#xD;
      Unfortunately, rTMS only has low to moderate efficacy; remission rates for patients range&#xD;
      from ~15-30% in large randomized controlled trials. The focus of this research is to develop&#xD;
      a next-generation rTMS protocol that is guided by the basic principles underlying brain&#xD;
      plasticity, in order to improve the efficacy of rTMS for the treatment of depression.&#xD;
      Specifically, in this study the investigators will test rTMS paired with a&#xD;
      depression-relevant cognitive state of internal attention. Meditative internal focus has been&#xD;
      shown to benefit depression. Our own research shows that the neural correlates of&#xD;
      attention-to-breath are associated with greater mindfulness. Hence, in this study we will&#xD;
      pair breath training with rTMS neuro-stimulation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 15, 2021</start_date>
  <completion_date type="Anticipated">July 15, 2025</completion_date>
  <primary_completion_date type="Anticipated">July 15, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized Controlled Trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline Clinical Depression</measure>
    <time_frame>up to 6 weeks</time_frame>
    <description>PHQ9 depression scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline brain activity in attention-to-breath task</measure>
    <time_frame>up to 6 weeks</time_frame>
    <description>Electroencephalography (EEG) power in theta-alpha band in attention-to-breath task</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Medi1TMS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rTMS theta-burst protocol paired with a consistent attention-to-breath task</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medi2TMS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>rTMS theta-burst protocol paired with an intermittent deep breathing task</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Medi1TMS</intervention_name>
    <description>rTMS theta-burst protocol paired with a consistent attention-to-breath task</description>
    <arm_group_label>Medi1TMS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Medi2TMS</intervention_name>
    <description>rTMS theta-burst protocol paired with an intermittent deep breathing task</description>
    <arm_group_label>Medi2TMS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  moderate to severe depression (PHQ-9 scale score &gt;9 with confirmation using the&#xD;
             Structured Clinical Interview for DSM-5 Disorders)&#xD;
&#xD;
          -  treatment refractory to antidepressants (i.e. failed 1-3 antidepressants in current&#xD;
             episode) or intolerant to antidepressants (i.e. tried 2 antidepressant of inadequate&#xD;
             dose/duration in current episode)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  active substance abuse/dependence&#xD;
&#xD;
          -  psychotic disorders&#xD;
&#xD;
          -  any factor that increases risk of TMS (metal implants/history of stroke/seizure&#xD;
             disorder).&#xD;
&#xD;
          -  displaying acutely suicidal behaviors on the Columbia Suicide Severity Rating Scale.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jyoti Mishra, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jyoti Mishra, PhD</last_name>
    <phone>(858) 822-0568</phone>
    <email>jymishra@ucsd.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dhakshin Ramanathan, MDPhD</last_name>
    <phone>(858) 822-0568</phone>
    <email>dramanathan@ucsd.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Neuromodulation Clinic Veterans Affairs San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dhakshin Ramanathan, MDPhD</last_name>
      <email>dramanathan@ucsd.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UC San Diego Health Psychiatry</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92127</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jyoti Mishra, PhD</last_name>
      <phone>858-822-0568</phone>
      <email>jymishra@ucsd.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 30, 2020</study_first_submitted>
  <study_first_submitted_qc>October 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2020</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Jyoti Mishra</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified raw and processed data will be shared with other researchers.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>At time of publication</ipd_time_frame>
    <ipd_access_criteria>The PI will review sharing requests and provide access to researchers.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

